No Data
"When will the 'medication' market return? Foreign capital and public offerings are racing to buy these pharmaceutical stocks.
The pharmaceutical industry has always been recognized as a "long slope and thick snow" track, and it is also one of the sectors that capital markets pay the most attention to.
Express News | Six institutions: improve the management of grassroots pharmaceuticals and expand the types of grassroots pharmaceuticals.
The bullish market stimulated the Hong Kong stock pharmaceutical sector, with Laikai Pharmaceutical soaring nearly 20%.
Statistics from the Capital Research Department of Silver (Hong Kong) show that the number of innovative drugs IND and NDA has returned to growth after hitting a low in 2022. In the third quarter of this year, 1033 drug clinical approvals were granted, a 25% year-on-year increase, with a total of 8 first-class innovative drugs approved for marketing, doubling year-on-year.
Will the indications of GLP-1 drugs expand to the field of PCOS? The era of three targets is about to arrive? | Industry Observation
①At the GLP-1 Drug Seminar (Chengdu session), participants discussed the global trend of GLP-1 drug research and development. ②Participants mentioned that the indications for GLP-1 drugs in the future may expand to areas such as PCOS and stroke. ③Drugs targeting GLP, GCG, and GIP receptors are beginning to rise.
Circ (01763): The new production line for the second phase of wuhan high-tech technetium-labeled pharmaceuticals has obtained certification for the production of radioactive pharmaceuticals.
Circ (01763) announced that on November 11, 2024, the company's holding subsidiary wuhan Atomic High-Tech...
Circ (01763): North China High Technology successfully obtained the radiation safety license issued by the Ministry of Eco-friendly Concept.
circ (01763) announced on November 14, 2024, that its subsidiary Atomic High-Tech is a wholly-owned subsidiary...
No Data
No Data